目的 评价膀胱癌抗原核基质蛋白22(NMP22)、尿膀胱癌抗原(UBC)、膀胱肿瘤抗原(BTA)在诊断膀胱癌中的应用价值.方法 应用酶联免疫吸附实验,检测膀胱癌疑似患者尿中NMP22、UBC、BTA的水平,并与健康组进行对比,评价NMP22、UBC、BTA的诊断价值.结果 膀胱癌患者 3项标志物联合检测敏感性96.9%(33/34),特异性80%(20/25),阳性预测值92.5%,阴性预测值90.9%;显著高于任何单一肿瘤标志物检测结果.NMP22、UBC水平和阳性率随着膀胱移行细胞癌分期、分级的升高而显著增加,BTA水平和阳性率在各分级和分期之间比较,差异无统计学意义.结论 尿NMP22、UBC、BTA检测可用于膀胱癌的诊断,三者联合检测对膀胱癌的诊断价值优于单一标志物进行检测.%Objective To evaluate the clinical value of NMP22,UBC and BTA in the early diagnosis of bladder cancer. Methods Enzyme linked immunosorbent assay was used to detect the concentration of NMP22, UBC and BTA in the urine of suspected pa tients,and the detected results were compared with that of healthy controls. Results The sensitivity,specificity and positive predictive value of the combination of NMP22, UBC and BTA in diagnosis of bladder cancer were 96.9％ (33/34), 80％ (20/25) and 92. 5％ ,and were higher of that any single tumor marker. The urinary levels and positive rates of NMP22 and UBC significantly in creased with the increase of stage and grade of transitional cell carcinoma of bladder(TCCB). Between different patients groups with TCCB at different stage and grade, there were no statistical difference of the urinary level and positive rate of BTA. Conclusion Urinary NMP22, UBC and BTA can be used for the diagnosis of bladder cancer,and the combined detection would be better than any single detection.
展开▼
